Tumor Infiltrating Lymphocytes Predicting Long-Term Outcomes in HER2-Negative Breast Cancer Patients with Visceral Metastases | ||
| Research in Oncology | ||
| Article 1, Volume 18, Issue 2, December 2022, Pages 45-51 PDF (390.25 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/resoncol.2022.135734.1166 | ||
| Authors | ||
| Elia F. Hakim* 1; Amina M. Mostafa2; Mohamed A. H. Mohamed2; Mahmoud F. A. Sherif3; Maha S. El Naggar2 | ||
| 1Department of Clinical Oncology, Sohag Cancer Center, Sohag, Egypt | ||
| 2Department of Clinical Oncology, Assuit University, Assuit, Egypt | ||
| 3Department of Pathology, Assuit University, Assuit, Egypt | ||
| Abstract | ||
| Background: Tumor-infiltrating lymphocytes (TILs) were found to be associated with a better clinical outcome in specific subtypes of breast cancer. Aim: To study the association between TILs and the prognosis of Egyptian patients with HER2-negative breast cancer metastatic to the viscera. Methods: This prospective study included 100 patients with HER2-negative metastatic breast cancer. Intratumoral TILs, stromal TILs, and CD4 and CD8 were examined in the pathological specimens and their relationship with survival and response to treatment was studied. Results: At a median follow-up period of 43 months, the median overall survival was 44.7 months (95%CI: 39.2-50.2) and the 5-year overall survival rate was 28%. A high level of CD8+ve TILs was associated with significantly longer overall survival (p < 0.001) and progression-free survival (p=0.043). There was no significant correlation between intratumoral TILs, stromal TILs, or CD4+ve and overall survival. Conclusions: A higher level of CD8+ve TILs is associated with better overall as well as progression-free survival in HER2-negative breast cancer with visceral metastases. | ||
| Keywords | ||
| Breast cancer; CD4; CD8; HER2; Prognosis; Tumor-infiltrating lymphocytes; Visceral metastases | ||
|
Statistics Article View: 502 PDF Download: 558 |
||
